You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.
The use of Anti Müllerian Hormone in the diagnosis of Polycystic Ovary Syndrome
Polycystic ovarian morphology (PCOM) is one of the three criteria used in PCOS diagnosis. While PCOM used to be only detected via imaging methods (mainly transvaginal ultrasound) now the guidelines suggest that the Anti-Müllerian Hormone (AMH) biomarker be used to identify PCOM as part of the diagnosis of PCOS. In this webinar Prof. Joop Laven provides detailed information on the use of AMH in the diagnosis of PCOM. Then Ms. Ferreira shares her insight on getting diagnosed with PCOS as a patient and will help us understand the burden of the disease from the patient's perspective.
Request medical material
Would you like to receive this poster via email to view later?